Global Barett's Esophagus Treatment Market -2023-2030

Overview

Barrett's esophagus is a condition in which the normal stratified squamous epithelium (pink lining or mucosal lining) of the oesophagus (food/swallowing pipe that connects mouth and stomach) is damaged by acid reflux and thickens and reddens, as detected on endoscopic examination and pathologically confirmed by the presence of intestinal metaplasia columnar epithelium (the presence of thick cells similar to those present in the intestine).

GERD is a condition, where the acid and bile from the stomach come back up through the lower oesophageal sphincter (LES), a critically important valve, present between the oesophagus and the stomach that prevents the reflux of gastric contents back into the oesophagus. The lining of the stomach is made of mucinous columnar epithelium, which can handle the acidic environment needed for digestion, whereas the lining of the oesophagus, on the other hand, is made of squamous epithelium.

Market Dynamics: Drivers and Restraints

Rise in the prevalence of gastroesophageal reflux disease (GERD)

The rise in the prevalence of gastroesophageal reflux diseases is one of the factors that drive the market growth during the forecast period. The prevalence of GERD is varied globally, which is estimated to be 23% in South America, 18% to 28% in North America, 12% in Australia, 2% to 7% in East Asia, 9% to 26% in Europe, and 9% to 33% in the Middle East the evidence suggests that the prevalence of GERD has significantly increased since 1995, especially in East Asia and North America. The prevalence of GERD in Saudi Arabia varied from 29% to 45%. In the Saudi population, the prevalence of GERD is substantially higher compared to western countries and East Asian countries.

Furthermore, technological advancements in treatments, changing lifestyles of people, increasing investment in healthcare infrastructure, rise in the number of geriatric populations, increasing research and developments and other will further drive the market growth further during the forecast period.

Market Dynamics: Restraint

Complications associated with the disease is one of the major restraining factors that hampers the market growth. Those who have barrett's esophagus are more likely to get esophageal cancer. Even in patients whose esophageal cells have undergone precancerous alterations, the danger is minimal. Fortunately, esophageal cancer seldom occurs in patients with barrett's esophagus. Also, lack of awareness, high cost of treatment, diagnostic challenges, limited treatment options and others will also be the restraint factors that hamper the market growth during the forecast period.

Segment Analysis

The global barett's esophagus treatment is segmented based on type, treatment, medication, sales channel and region.

The low-grade dysplasia from the type segment accounted for approximately 41.2% of the market share

The low-grade dysplasia from the type segment accounted for 41.2% and it is expected to be dominated during the forecast period. Low-grade dysplasia means that some of the cells look abnormal. These cells may look like cancer cells in some ways, but unlike cancer, they don't have the ability to spread to other parts of your body. This is a very early pre-cancer of the esophagus.

For instance, in August 2023, Castle Biosciences, Inc. a company improving health through innovative tests that guide patient care, stated a new study published in The American Journal of Gastroenterology showing how use of tissuecypher barrett's esophagus test results can significantly improve management decisions for barrett's esophagus patients with low-grade dysplasia (LGD) to improve health outcomes.

Geographical Analysis

North America accounted for approximately 38.4% of the market share in 2022

North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to the factors such as obesity, gastroesophageal reflux disease (GERD), and smoking. As the population continues to age, the demand for treatment for Barrett's esophagus with dysplasia is expected to increase. Due to this, there have been significant advancements in endoscopic technologies and treatments for barrett's esophagus with dysplasia in North America, including radiofrequency ablation (RFA), cryotherapy, and endoscopic mucosal resection (EMR).

Furthermore, North America has a strong healthcare infrastructure, with well-trained healthcare providers and access to advanced medical technologies. For instance, in August 2023, esophageal and stomach cancer rates have increased significantly in the US and other western countries over the past five decades.

Esophageal adenocarcinoma and GCA are highly fatal cancers. However, research scientist Joel Rubenstein suggests that preventative measures can help. Screening can identify pre-cancerous changes in patients, such as barrett's esophagus, which can be diagnosed in those with long-term gastroesophageal reflux disease (GERD).

COVID-19 Impact Analysis

The COVID-19 pandemic has dramatically impacted gastroenterology services worldwide. As coronavirus infection rates rose, many professional bodies advised that all endoscopy, except emergency and essential procedures, be stopped immediately. Upper gastrointestinal endoscopy was considered a high-risk procedure due to a greater potential for aerosolization and transmission of the SARS-CoV-2 virus .

Competitive Landscape

The major global players in the barett's esophagus treatment market include: Novartis AG, Advacarepharma, Apotex, Takeda Pharmaceutical Company Limited, Woodward Pharma Services LLC,Steris, Medtronic Plc, Stryker, Boston Scientific, Olympus and among others.

Key Developments

• In August 2022, the American College of Gastroenterology released new guidelines for Barrett's esophagus, which suggest expanding the screening methods beyond endoscopic procedures, increasing the frequency of surveillance for short-segment Barrett's esophagus, and implementing volume criteria for endoscopic therapy centres.
• In January 2022, Researchers unmask the cellular source of barrett's esophagus. Two recent studies by Dana-Farber Cancer Institute scientists correct a longstanding misconception about the origins of barrett's esophagus, and in doing so may point to new avenues of treatment or prevention to lower the risk of esophageal cancer.
• In June 2020, Cernostics stated blinded, independent validation of tissuecypher performance for predicting risk of progression to esophageal cancer in patients with non-dysplastic be.

Why Purchase the Report?

• To visualize the global barett's esophagus treatment market segmentation-based type, treatment, medication, sales channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of barett's esophagus treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global barett's esophagus treatment market report would provide approximately 69 tables, 70 figures, and 185 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies